|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...2526272829303132333435...4041» |
- methylphenidate tablet / Generic mfg.
Enrollment open: Methylphenidate to Improve Balance and Walking in MS (clinicaltrials.gov) - Jul 9, 2013
P2/3, N=24, Recruiting, Sponsor: Oregon Health and Science University
Not yet recruiting --> Recruiting
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Jul 9, 2013
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| teriflunomide / Generic mfg.
New P4 trial, Patient reported outcomes: TERI-PRO: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Jul 8, 2013
P4, N=1000, Recruiting, Sponsor: Sanofi
- New P2 trial: Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis (clinicaltrials.gov) - Jul 8, 2013
P2, N=30, Recruiting, Sponsor: University of Jordan
- Trial completion: Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients (clinicaltrials.gov) - Jul 8, 2013
P=N/A, N=17, Completed, Sponsor: Kirsten Gruis
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jul 8, 2013
P1, N=60, Completed, Sponsor: University of Michigan
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis (clinicaltrials.gov) - Jul 2, 2013
P2, N=30, Recruiting, Sponsor: University of Jordan
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial withdrawal: Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=0, Withdrawn, Sponsor: Paul Farand
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Enrollment change: Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients (clinicaltrials.gov) - Jul 2, 2013
P=N/A, N=0, Withdrawn, Sponsor: Paul Farand
Not yet recruiting --> Withdrawn N=30 --> 0
- | NurOwn (MSC-NTF) / BrainStorm Cell Therap
Enrollment change, Stroma: Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. (clinicaltrials.gov) - Jul 1, 2013
P1/2, N=12, Completed, Sponsor: Hadassah Medical Organization
N=30 --> 0 N=24 --> 12
- | NurOwn (MSC-NTF) / BrainStorm Cell Therap
Trial completion, Stroma: Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. (clinicaltrials.gov) - Jul 1, 2013
P1/2, N=12, Completed, Sponsor: Hadassah Medical Organization
N=24 --> 12 Active, not recruiting --> Completed
- ||||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P2 trial: Extension Study of MT-1303 (clinicaltrials.gov) - Jun 30, 2013
P2, N=400, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Trial completion: High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jun 30, 2013
P2, N=28, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
New P4 trial: Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations (clinicaltrials.gov) - Jun 25, 2013
P4, N=40, Recruiting, Sponsor: The University of Texas Health Science Center, Houston
- |||| Trial completion: An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 25, 2013
P2, N=143, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Enrollment open: Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations (clinicaltrials.gov) - Jun 23, 2013
P4, N=40, Recruiting, Sponsor: The University of Texas Health Science Center, Houston
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- paquinimod (ABR-215757) / Active Biotech
Biomarker, Enrollment change: An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod) (clinicaltrials.gov) - Jun 23, 2013
P2, N=9, Completed, Sponsor: Active Biotech AB
Not yet recruiting --> Recruiting N=20 --> 9
- paquinimod (ABR-215757) / Active Biotech
Biomarker, Trial completion: An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod) (clinicaltrials.gov) - Jun 23, 2013
P2, N=9, Completed, Sponsor: Active Biotech AB
N=20 --> 9 Recruiting --> Completed
- | Tysabri (natalizumab) / Biogen, Royalty
New P1 trial: PK and PD Study of Natalizumab in Pediatric Subjects With RRMS (clinicaltrials.gov) - Jun 20, 2013
P1, N=12, Recruiting, Sponsor: Biogen Idec
- Enrollment change: IRM 3T-SEP: Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy (clinicaltrials.gov) - Jun 19, 2013
P=N/A, N=6, Completed, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed N=10 --> 6
- Trial completion: IRM 3T-SEP: Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy (clinicaltrials.gov) - Jun 19, 2013
P=N/A, N=6, Completed, Sponsor: Hospices Civils de Lyon
N=10 --> 6 Recruiting --> Completed
- teriflunomide / Generic mfg.
Clinical: Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=50, Recruiting, Sponsor: University at Buffalo
- New P2 trial: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) - Jun 17, 2013
P2, N=40, Suspended, Sponsor: University Hospital of Ferrara
- | Avonex (recombinant IFN-?-1a) / Biogen
Enrollment change, Combination therapy: Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis (clinicaltrials.gov) - Jun 16, 2013
P2, N=43, Completed, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Completed N=60 --> 43
- | Avonex (recombinant IFN-?-1a) / Biogen
Trial completion, Combination therapy: Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis (clinicaltrials.gov) - Jun 16, 2013
P2, N=43, Completed, Sponsor: University of Texas Southwestern Medical Center
N=60 --> 43 Active, not recruiting --> Completed
- | riluzole / Generic mfg., rasagiline / Generic mfg.
New P2 trial: Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jun 13, 2013
P2, N=250, Recruiting, Sponsor: University of Ulm
- || New P3 trial: Gastroesophageal Reflux Treatment in Scleroderma (clinicaltrials.gov) - Jun 13, 2013
P3, N=250, Recruiting, Sponsor: Khon Kaen University
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Enrollment closed: Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 12, 2013
P2, N=232, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control (clinicaltrials.gov) - Jun 11, 2013
P=N/A, N=164, Completed, Sponsor: John F. Foley, MD
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change: Functional and Physiological Responses to Lokomat Therapy (Pilot Study) (clinicaltrials.gov) - Jun 9, 2013
P=N/A, N=27, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed N=80 --> 27
- ||||| Cosentyx (secukinumab) / Novartis
New P2 trial: Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 9, 2013
P2, N=380, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| dimethyl fumarate / Generic mfg.
New P4 trial: MANAGE: Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (clinicaltrials.gov) - Jun 6, 2013
P4, N=230, Active, not recruiting, Sponsor: Biogen Idec
- |||||||||| Copaxone 3TW (glatiramer acetate three times a week) / Teva
New P3 trial: Safety and Tolerability of Glatiramer Acetate (clinicaltrials.gov) - Jun 6, 2013
P3, N=210, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
- | teriflunomide / Generic mfg.
Trial termination: TERACLES: Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta (clinicaltrials.gov) - Jun 5, 2013
P3, N=1455, Terminated, Sponsor: Sanofi
N=80 --> 27 Completed --> Terminated; Sponsor decision to prematurely stop the study, not linked to any safety concern.
- Clinical: A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=240, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- | Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
Trial initiation date: CEASE-MS: Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jun 4, 2013
P2a, N=16, Recruiting, Sponsor: RedHill Biopharma Limited
Completed --> Terminated; Sponsor decision to prematurely stop the study, not linked to any safety concern. Initiation date: Jan 2013 --> Jun 2013
- Clinical: Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=34, Not yet recruiting, Sponsor: Hadassah Medical Organization
- | Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
Enrollment open: CEASE-MS: Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jun 4, 2013
P2a, N=16, Recruiting, Sponsor: RedHill Biopharma Limited
Initiation date: Jan 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- |||||||||| Sativex (nabiximols) / Jazz
New P3 trial, P3 data: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (clinicaltrials.gov) - Jun 2, 2013
P3, N=711, Not yet recruiting, Sponsor: GW Pharmaceuticals Ltd.
- Enrollment change: The Effect of Anodal tDCS on Motor Learning in Multiple Sclerosis (clinicaltrials.gov) - May 31, 2013
P=N/A, N=31, Completed, Sponsor: Hasselt University
Not yet recruiting --> Recruiting N=10 --> 31
- Trial completion: Functional and Physiological Responses to Lokomat Therapy (Pilot Study) (clinicaltrials.gov) - May 30, 2013
P=N/A, N=27, Completed, Sponsor: Department of Veterans Affairs
N=10 --> 31 Active, not recruiting --> Completed
- GSK239512 / GSK
Enrollment change: GSK239512 DDI Study (clinicaltrials.gov) - May 29, 2013
P1, N=22, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=16 --> 22
- | GSK239512 / GSK
Trial completion: GSK239512 DDI Study (clinicaltrials.gov) - May 29, 2013
P1, N=22, Completed, Sponsor: GlaxoSmithKline
N=16 --> 22 Recruiting --> Completed
- Clinical: SCI-COG: Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI (clinicaltrials.gov) - May 28, 2013
P=N/A, N=120, Recruiting, Sponsor: University Hospital, Bordeaux
- Clinical: Acupuncture or MBSR for Patients With Fatigue and MS (clinicaltrials.gov) - May 28, 2013
P=N/A, N=141, Recruiting, Sponsor: Charite University, Berlin, Germany
- | New P1/2 trial: Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients (clinicaltrials.gov) - May 28, 2013
P1/2, N=100, Recruiting, Sponsor: University of British Columbia
- dalfampridine / Generic mfg.
Enrollment open: Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis (clinicaltrials.gov) - May 28, 2013
P=N/A, N=50, Recruiting, Sponsor: Carmel Medical Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| teriflunomide / Generic mfg.
New P3 trial, Immune cell: Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis (clinicaltrials.gov) - May 27, 2013
P3, N=68, Recruiting, Sponsor: Sanofi
- ||||| opicinumab (BIIB033) / Biogen, Avonex (recombinant IFN-β-1a) / Biogen
New P2 trial: SYNERGY: Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (clinicaltrials.gov) - May 27, 2013
P2, N=396, Recruiting, Sponsor: Biogen Idec
- Biomarker, Enrollment closed: USPIO-CIS: The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System. (clinicaltrials.gov) - May 27, 2013
P=N/A, N=50, Active, not recruiting, Sponsor: Rennes University Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting